Chimerix to Present at the Stifel 2018 Healthcare Conference
November 07 2018 - 8:14AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing
novel antivirals for the growing population of immunocompromised
patients, today announced that M. Michelle Berrey, M.D.,
M.P.H., Chief Executive Officer and Tim Trost, Chief
Financial Officer will participate in a fireside chat at the Stifel
2018 Healthcare Conference on Wednesday, November 14,
2018 at 9:30 a.m. ET at the Lotte New York
Palace Hotel in New York City.
A live audio webcast of the presentation will be available on
the Investor Relations section of Chimerix’s website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to
discovering, developing and commercializing medicines that improve
outcomes for immunocompromised
patients. Chimerix's proprietary lipid conjugate
technology and compound library have produced brincidofovir (BCV,
CMX001); CMX157, which was licensed to ContraVir
Pharmaceuticals; and CMX521, the first clinical-stage direct-acting
antiviral for the treatment and prevention of norovirus. For
further information, please
visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:Michelle LaSpaluto(919) 972-7115
ir@chimerix.com or Will O’Connor Stern Investor Relations
Will@sternir.com (212) 362-1200
Media: Laurie Masonson W2O Group lmasonson@w2ogroup.com (917)
459-6164
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024